Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo

Journal of Controlled Release

Volumn 142, Issue 2, 2010, Pages 267-276

  Obata, Yosuke ^a   Tajima, Shoji ^a   Takeoka, Shinji ^a  

^a WASEDA UNIVERSITY   (Japan)

Author keywords

Amino lipid; Drug delivery; Liposomes; PH responsive; Zwitterionic lipid

Indexed keywords

ACIDIC PH; AMINO LIPID; ANIONIC MEMBRANES; ANTI-TUMOR EFFICACY; BREAST CANCER TUMORS; CANCER CELL GROWTH; DOXORUBICIN; DRUG DELIVERY SYSTEM; ENDOSOMAL PH; ENDOSOMES; GLUTAMIC ACID; IN-VITRO; IN-VIVO; INTRACELLULAR DRUG DELIVERY; L-GLUTAMATE; MICROSCOPIC STUDY; PC-BASED; PH VALUE; PH-RESPONSIVE; SOLUTION PH; ZWITTERIONIC LIPID; ZWITTERIONIC LIPIDS;

AMINO ACIDS; BLOOD; CELLS; CLARIFICATION; CYTOLOGY; DRUG DELIVERY; GROWTH KINETICS; LIPOSOMES; ORGANIC ACIDS; ZETA POTENTIAL;

PHOSPHOLIPIDS;

1,5 DIHEXADECYL N GLUTAMYL GLUTAMIC ACID; 1,5 DIHEXADECYL N,N DIGLUTAMYL LYSYL GLUTAMIC ACID; DOXORUBICIN; LIPID; LIPOSOME; PHOSPHOLIPID; UNCLASSIFIED DRUG; ZWITTERIONIC LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL MEMBRANE; CELL NUCLEUS; CELL VIABILITY; CHEMICAL STRUCTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENCAPSULATION; ENDOSOME; FEMALE; HELA CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SYNTHESIS; TUMOR XENOGRAFT; ZETA POTENTIAL;

AMINO ACIDS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; FEMALE; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPIDS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR;

EID: 76749120847     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.10.023     Document Type: Article

References (55)

1. Torchilin V.P. Recent advances with liposomes as pharmaceutical carries. Nat. Rev. 2005, 4:145-160.
2. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 2006, 58:1532-1555.
3. Chonn A., Cullis P.R. Recent advances in liposome technologies and their applications for systemic gene delivery. Adv. Drug Deliv. Rev. 1998, 30:73-83.
4. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
5. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
6. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Deliv. Today 2006, 11:812-818.
7. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 2007, 59:748-758.
8. Nakanishi M., Nogichi A. Confocal and probe microscopy to study gene transfection mediated by cationic liposomes with a cationic cholesterol derivative. Adv. Drug Deliv. Rev. 2001, 52:197-207.
9. Almofti M.R., Harashima H., Shinohara Y., Almofti A., Baba Y., Kiwada H. Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization. Arch. Biochem. Biophys. 2003, 410:246-253.
10. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35:5616-5623.
11. Koynova R., Wang L., MacDonald R.C. An intracellular lamellar-nonlamellar phase transition rationalizes the superior performance of some cationic lipid transfection agents. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14,373-14,378.
12. Li S., Tseng W.-C., Beer Stolz D., Wu S.-P., Watkins S.C., Huang L. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. Gene Ther. 1999, 6:585-594.
13. Wu J., Lizarzaburu M.E., Kurth M.J., Liu L., Wege H., Zern M.A., Nantz M.H. Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents. Bioconjug. Chem. 2001, 12:251-257.
14. Eliyahu H., Joseph A., Schillemans J.P., Azzam T., Domb A.J., Barenholz Y. Characterization and in vivo performance of dextran-spermine polyplexes and DOTAP/cholesterol lipoplexes administered locally and systemically. Biomaterials 2007, 28:2339-2349.
15. Lampela P., Soininen P., Urtti A., Männistö P.T., Raasmaja A. Synergism in gene delivery by small PEIs and three different nonviral vectors. Int. J. Pharm. 2004, 270:175-184.
16. Vlerken L.E., Vyas T.K., Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 2007, 24:1405-1414.
17. Okuda T., Kawakami S., Akimoto N., Niidome T., Yamashita F., Hashida M. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J. Control. Release 2006, 116:330-336.
18. Roux E., Passirani C., Scheffold S., Benoit J.P., Leroux J.C. Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J. Control. Release 2004, 94:447-451.
19. Wang X.Y., Ishida T., Ichihara M., Kiwada H. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J. Control. Release 2005, 5:91-102.
20. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1113:171-199.
21. Obata Y., Suzuki D., Takeoka S. Evaluation of cationic assemblies constructed with amino-acid based lipids for plasmid DNA delivery. Bioconjug. Chem. 2008, 19:1055-1063.
22. Obata Y., Saito S., Takeda N., Takeoka S. Plasmid DNA-encapsulating liposomes: effect of a spacer between the cationic head group and hydrophobic moieties of the lipids on gene expression efficiency. Biochim. Biophys. Acta Biomembr. 2009, 1788:1148-1158.
23. Y. Obata, G. Ciofani, V. Raffa, A. Cuschieri, A. Menciassi, P. Dario, S. Takeoka, Evaluation of cationic liposomes composed of an amino-acid based lipid for neuronal transfection, Nanomedicine. doi:10.1016/j.nano.2009.04.005.
24. Leventis R., Silvirus J.R. Interactions of mammalian cells with lipid dispersion containing metabolizable cationic amphiphiles. Biochim. Biophys. Acta 1990, 1023:124-132.
25. Okamura Y., Maekawa I., Teramura Y., Maruyama H., Handa M., Ikeda Y., Takeoka S. Hemostatic effects of phospholipid vesicles carrying fibrinogen γ-chain dodecapeptide in vitro and in vivo. Bioconjug. Chem. 2005, 16:1589-1596.
26. Struck D.K., Hoekstra D., Pagano R.E. Use of resonance energy transfer to monitor membrane fusion. Biochemistry 1981, 20:4093-4099.
27. Rajesh M., Sen J., Srujan M., Mukherjee K., Sreedhar B., Chaudhuri A. Dramatic influence of the orientation of linker between hydrophilic and hydrophobic lipid moiety in liposomal gene delivery. J. Am. Chem. Soc. 2007, 129:11,408-11,420.
28. Ulrich H., Ansgar W., Yuval G., Rolf S., Regine P.-S. Fourier transformed spectral bio-imaging for studying the intracellular fate of liposomes. Cytometry Part A 2004, 57A:10-21.
29. McIntosh A.L., Gallegos A.M., Atshaves B.P., Storey S.M., Kannoju D., Schroeder F. Fluorescence and multiphoton imaging resolve unique structural forms of sterol in membranes of living cells. J. Biol. Chem. 2003, 278:6384-6403.
30. Oishi M., Kataoka K., Nagasaki Y. pH-Responsive three-layered PEGylated polyplex Micelle based on a lactosylated ABC triblock copolymer as a targetable and endosome-disruptive nonviral gene vector. Bioconjug. Chem. 2006, 17:677-688.
31. Dawson R.M.C., Elliott D.C., Elliott W.H., Jones K.M. Data for Biochemical Research 1986, Oxford Science Publications, p131. 3rd ed.
32. Dubin P., Bock J., Davis R., Schulz D.N., Thies C. Macromolecular Complexes in Chemistry and Biology 1994, Springer-Verlag Berlin Heidelberg, p188.
33. Wasungu L., Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release 2006, 116:255-264.
34. Bergstrand N., Arfvidsson M.C., Kim J.-M., Thompson D.H., Edwards K. Interactions between pH-sensitive liposomes and model membranes. Biophys. Chemist. 2003, 104:361-379.
35. Li X., Hirsh D.J., Cabral-Lilly D., Zirkel A., Gruner S.M., Janoff A.S., Perkins W.R. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim. Biophys. Acta 1998, 1415:23-40.
36. Voûte P.A., Souhami R.L., Nooij M., Somers R., Cortés-Funes H., van der Eijken J.W., Pringle J., Hogendoorn P.C., Kirkpatrick A., Uscinska B.M., van Glabbeke M., Machin D., Weeden S. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann. Oncol. 1999, 10:1211-1218.
37. Bruynzeel A.M., Niessen H.W., Bronzwaer J.G., van der Hoeven J.J., Berkhof J., Bast A., van der Vijgh W.J., van Groeningen C.J. The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br. J. Cancer 2007, 97:1084-1089.
38. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attribute to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.
39. Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.L., Carter P., Benz C.C., Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1996, 36:66-75.
40. Yoshimura T., Shono M., Imai K., Hong K. Kinetic analysis of endocytosis and intracellular fate of liposomes in single macrophages. J. Biochem. 1995, 117:34-41.
41. Simões S., Moreira J.N., Fonseca C., DüzgüneŞ N., Pedroso de Lima M.C. On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 2004, 56:947-965.
42. Shi G., Guo W., Stephenson S.M., Lee R.J. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J. Control. Release 2002, 80:309-319.
43. Hafez I.M., Ansell S., Cullis P.R. Tunable pH-sensitive liposome composed of mixtures of cationic and anionic lipids. Biophys. J. 2000, 79:1438-1446.
44. Sudimack J.J., Guo W., Tjarks W., Lee R.J. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim. Biophys. Acta 2002, 1564:31-37.
45. Ishida T., Kirchmeier M.J., Moase E.H., Zalipsky S., Allen T.M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta 2001, 1515:144-158.
46. Reddy J.A., Low P.S. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J. Control. Release 2000, 64:27-37.
47. Green A.E., Rose P.G. Pegylated liposomal doxorubicin in ovarian cancer. Int. J. Nanomedicine 2006, 1:229-239.
48. Udhrain A., Skubitz K.M., Northfelt D.W. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int. J. Nanomedicine 2006, 2:345-352.
49. Recchia F., Filippis S.D., Saggio G., Amiconi G., Cesta A., Carta G., Rea S. Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer. Anticancer Drugs 2003, 14:633-638.
50. Chin D.L., Lum B.L., Sikic B.I. Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. J Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 5:259-269.
51. Liu Y., Yang Y., Liu X., Jiang T. Quantification of pegylated liposomal doxorubicin and doxorubicinol in rat plasma by liquid chromatography/electrospray tandem mass spectroscopy: application to preclinical pharmacokinetic studies. Talanta 2008, 74:887-895.
52. Kim H.S., Song I.H., Kim J.C., Kim E.J., Jang D.O., Park Y.S. In vitro and in vivo gene-transferring characteristics of novel cationic lipids, DMKD (O,O'-dimyristyl-N-lysyl aspartate) and DMKE (O,O'-dimyristyl-N-lysyl glutamate). J. Control. Release 2006, 115:234-241.
53. Song Y.K., Liu F., Chu S., Liu D. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum. Gene Ther. 1997, 8:1585-1594.
54. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.-D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:11,460-11,464.
55. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.